Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director | June 24, 2026 | June 26, 2026 |
| Nkarta, Inc.NKTX · Entity 6346 | Director | June 08, 2022 | June 10, 2022 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 03, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23 | Direct | 30,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Nkarta, Inc.
Report date June 08, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2032-06-07 | Direct | 16,000 |
Reported balance
After 2022-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).
Relay Therapeutics, Inc.
Report date June 03, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2034-06-02 | Direct | 102,225 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 102,225 · Balance 102,225 F1: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Synthorx, Inc.
Report date January 23, 2020 · Filed January 24, 2020
Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,595 |
Reported balance
After 2020-01-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-01-08 · Gift · Disposed 80,706 · Balance 215,595 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-01-23 · Other · Disposed 220,595 · Balance 0 F1: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Laura K. Shawver Trust DTD 3/20/2000 | 0 |
Reported balance
After 2020-01-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-23 · Other · Disposed 25,000 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2028-05-16 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-23 · Disposition to issuer · Disposed 293,177 · Balance 0 F2: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-23 · Disposition to issuer · Disposed 172,264 · Balance 0 F3: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-12-05 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-23 · Disposition to issuer · Disposed 385,185 · Balance 0 F4: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F3: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F4: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2023 Filed Aug 3, 2023 22:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 36,281 | $1.27 | $46,076.87 |
DisclosureSEC source: 0001209191-23-044534 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 246,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 22:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,715 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-044534 · doc4.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,282 Underlying: Common Stock · 18,715 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 22:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 18,715 | $7.19 | $134,575.82 |
DisclosureSEC source: 0001209191-23-044534 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.11 to $7.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 22:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 18,715 | $1.27 | $23,768.05 |
DisclosureSEC source: 0001209191-23-044534 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2023 Filed Jul 8, 2023 00:16 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,858 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-041866 · doc4.xml · derivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,997 Underlying: Common Stock · 8,858 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 07, 2023 Filed Jul 8, 2023 00:16 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 8,858 | $6.36 | $56,372.31 |
DisclosureSEC source: 0001209191-23-041866 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.21 to $6.56, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| July 07, 2023 Filed Jul 8, 2023 00:16 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 8,858 | $1.27 | $11,249.66 |
DisclosureSEC source: 0001209191-23-041866 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,510 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · derivative · entry 9 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,855 Underlying: Common Stock · 33,510 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 33,510 | $6.34 | $212,553.93 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · nonDerivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.10 to $6.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 33,510 | $1.27 | $42,557.70 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · nonDerivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,112 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · derivative · entry 8 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,365 Underlying: Common Stock · 31,112 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 31,112 | $6.41 | $199,552.37 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.21 to $6.75, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 31,112 | $1.27 | $39,512.24 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,520 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · derivative · entry 7 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,477 Underlying: Common Stock · 26,520 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 03, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 26,520 | $6.73 | $178,347.00 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.62 to $6.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| July 03, 2023 Filed Jul 7, 2023 00:55 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 26,520 | $1.27 | $33,680.40 |
DisclosureSEC source: 0001209191-23-041716 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 01:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-040110 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 23:48 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,941 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-034090 · doc4.xml · derivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,997 Underlying: Common Stock · 26,941 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 23:48 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 26,941 | $6.95 | $187,239.95 |
DisclosureSEC source: 0001209191-23-034090 · doc4.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.73 to $7.22, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 23:48 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 26,941 | $1.27 | $34,215.07 |
DisclosureSEC source: 0001209191-23-034090 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:48 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 73,059 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-034090 · doc4.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,938 Underlying: Common Stock · 73,059 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:48 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 73,059 | $6.80 | $496,801.20 |
DisclosureSEC source: 0001209191-23-034090 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.60 to $7.07, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:48 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 73,059 | $1.27 | $92,784.93 |
DisclosureSEC source: 0001209191-23-034090 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 22:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 66,055 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001209191-23-033432 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,055 Underlying: Common Stock · 66,055 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GiftCommon Stock | 12,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-032515 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · kind: Reflects the gift of common stock to a charitable foundation. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,900 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · derivative · entry 7 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,997 Underlying: Common Stock · 42,900 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 42,900 | $5.31 | $227,799.00 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F3 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.00 to $5.92, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 42,900 | $1.27 | $54,483.00 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,100 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · derivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,897 Underlying: Common Stock · 57,100 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 57,100 | $6.16 | $351,736.00 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F3 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $6.00 to $6.44, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 57,100 | $1.27 | $72,517.00 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2022 Filed May 10, 2023 20:53 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 43,896 | $4.58 | $201,043.68 |
DisclosureSEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · shares: Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.53 to $5.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:38 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | Exercise / conversionStock option (right to buy) · Derivative | 78,740 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-045023 · doc4.xml · derivative · entry 2 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,997 Underlying: Common Stock · 78,740 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on April 16, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:38 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | Exercise / conversionCommon Stock | 78,740 | $1.27 | $99,999.80 |
DisclosureSEC source: 0001209191-22-045023 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:10 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-035844 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| May 27, 2022 Filed May 27, 2022 21:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 41,597 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001209191-22-032674 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Common Stock · 41,597 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:19 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 136,214 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027168 · doc4.xml · derivative · entry 2 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,214 Underlying: Common Stock · 136,214 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:19 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantCommon Stock | 68,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027168 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,502 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:17 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 104,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006435 · doc4.xml · derivative · entry 3 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Stock · 104,500 shares Expires 2032-01-31 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:17 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 165,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006435 · doc4.xml · derivative · entry 2 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-01-31 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:17 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006435 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,395 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 682 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| June 13, 2021 Filed Jun 15, 2021 14:25 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 16,511 | $0.00 Strike: $25.03 | $0.00 |
DisclosureSEC source: 0000899243-21-023797 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,511 Underlying: Common Stock · 16,511 shares Expires 2031-06-12 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 13, 2022, or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| May 19, 2021 Filed May 21, 2021 23:46 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001209191-21-035116 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 00:59 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 562,631 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062053 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,631 Underlying: Common Stock · 562,631 shares Expires 2030-12-02 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020. Read SEC document |
| July 09, 2020 Filed Jul 14, 2020 01:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 18,300 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019029 · doc4.xml · derivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 18,300 shares Expires 2030-07-08 F2 · derivative.exercise_date: All shares subject to the option vest 100% on the first anniversary of July 1, 2020, or, if earlier, on the day immediately preceding the first annual meeting of the Issuer's stockholders in 2021 at which one or more members of the Issuer's board of directors are to be elected. Each grant, to the extent outstanding and otherwise unvested, will become fully vest should a "change in control" of the Issuer occur (as defined in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as defined in the applicable award agreement). Read SEC document |
| July 09, 2020 Filed Jul 14, 2020 01:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 10,700 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019029 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Underlying: Common Stock · 10,700 shares Expires 2030-07-08 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first anniversary of July 9, 2020, or, if earlier, on the day immediately preceding the first annual meeting of the Issuer's stockholders in 2021 at which one or more members of the Issuer's board of directors are to be elected. Each grant, to the extent outstanding and otherwise unvested, will become fully vest should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 23:41 UTC | Synthorx, Inc. THOR · Entity 152202 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 385,185 | $57.00 Strike: $11.00 | $21,955,545.00 |
DisclosureSEC source: 0001209191-20-004929 · doc4.xml · derivative · entry 6 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 385,185 shares Expires 2028-12-05 F4 · derivative.exercise_date: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 23:41 UTC | Synthorx, Inc. THOR · Entity 152202 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 172,264 | $67.37 Strike: $0.63 | $11,605,425.68 |
DisclosureSEC source: 0001209191-20-004929 · doc4.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 172,264 shares Expires 2027-12-06 F3 · derivative.exercise_date: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 23:41 UTC | Synthorx, Inc. THOR · Entity 152202 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 293,177 | $67.07 Strike: $0.93 | $19,663,381.39 |
DisclosureSEC source: 0001209191-20-004929 · doc4.xml · derivative · entry 4 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,177 shares Expires 2028-05-16 F2 · derivative.exercise_date: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 23:41 UTC | Synthorx, Inc. THOR · Entity 152202 | OtherCommon Stock | 25,000 | $68.00 | $1,700,000.00 |
DisclosureSEC source: 0001209191-20-004929 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Laura K. Shawver Trust DTD 3/20/2000 Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.